195 related articles for article (PubMed ID: 30173322)
1. ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.
Kirn V; Strake L; Thangarajah F; Richters L; Eischeid H; Koitzsch U; Odenthal M; Fries J
Clin Exp Metastasis; 2018 Oct; 35(7):707-712. PubMed ID: 30173322
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
3. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
Shenker NS; Flower KJ; Wilhelm-Benartzi CS; Dai W; Bell E; Gore E; El Bahrawy M; Weaver G; Brown R; Flanagan JM
BMC Cancer; 2015 May; 15():337. PubMed ID: 25927974
[TBL] [Abstract][Full Text] [Related]
5.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
10. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas.
Moreira-Dinzey J; Zhan H; Rozenblit M; Krishnamurti U; Harigopal M; Zhong M; Liang Y
Hum Pathol; 2023 Jul; 137():56-62. PubMed ID: 37127079
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Sheng X; Guo Y; Lu Y
Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
[TBL] [Abstract][Full Text] [Related]
12.
Bos MK; Deger T; Sleijfer S; Martens JWM; Wilting SM
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628441
[No Abstract] [Full Text] [Related]
13. Epigenetic Changes of the ESR1 Gene in Breast Tissue of Healthy Women: A Missing Link with Breast Cancer Risk Factors?
Daraei A; Izadi P; Khorasani G; Nafissi N; Naghizadeh MM; Younosi N; Meysamie A; Mansoori Y; Bastami M; Tavakkoly-Bazzaz J
Genet Test Mol Biomarkers; 2017 Aug; 21(8):464-470. PubMed ID: 28708432
[TBL] [Abstract][Full Text] [Related]
14. p53 Binds to estrogen receptor 1 promoter in human breast cancer cells.
Rasti M; Arabsolghar R; Khatooni Z; Mostafavi-Pour Z
Pathol Oncol Res; 2012 Apr; 18(2):169-75. PubMed ID: 21655924
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.
Kirn V; Shi R; Heublein S; Knabl J; Guenthner-Biller M; Andergassen U; Fridrich C; Malter W; Harder J; Friese K; Mayr D; Jeschke U
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1681-7. PubMed ID: 24908329
[TBL] [Abstract][Full Text] [Related]
16. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
17. ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer.
Medina-Jaime AD; Reyes-Vargas F; Martinez-Gaytan V; Zambrano-Galvan G; Portillo-Delcampo E; Burciaga-Nava JA; Reyes-Romero M; Sifuentes-Alvarez A
Asian Pac J Cancer Prev; 2014; 15(7):3041-4. PubMed ID: 24815444
[TBL] [Abstract][Full Text] [Related]
18. Tissue-Specific Expression of Estrogen Receptor 1 Is Regulated by DNA Methylation in a T-DMR.
Maekawa R; Sato S; Okada M; Lee L; Tamura I; Jozaki K; Kajimura T; Asada H; Yamagata Y; Tamura H; Yamamoto S; Sugino N
Mol Endocrinol; 2016 Mar; 30(3):335-47. PubMed ID: 26683811
[TBL] [Abstract][Full Text] [Related]
19. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
Chu D; Paoletti C; Gersch C; VanDenBerg DA; Zabransky DJ; Cochran RL; Wong HY; Toro PV; Cidado J; Croessmann S; Erlanger B; Cravero K; Kyker-Snowman K; Button B; Parsons HA; Dalton WB; Gillani R; Medford A; Aung K; Tokudome N; Chinnaiyan AM; Schott A; Robinson D; Jacks KS; Lauring J; Hurley PJ; Hayes DF; Rae JM; Park BH
Clin Cancer Res; 2016 Feb; 22(4):993-9. PubMed ID: 26261103
[TBL] [Abstract][Full Text] [Related]
20. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]